Global /Australia /Healthcare /Drug Manufacturers - General /BIO

Biome Australia Ltd.

BIO

• ASX: BIO • Delayed

0.2950AUD -1.7%

0.2105 USD

As of 5 June 2026, Biome Australia Ltd. has a market cap of $48.81M USD, ranking #30772 globally and #764 in Australia. It ranks #2780 in the Healthcare sector, and #975 in the Drug Manufacturers - General industry.

Global Rank

30772

Country Rank

764

Sector Rank

2780

Industry Rank

975

Key Stats

Market Cap

$48.81MUSD

68.4M AUD

Enterprise Value

$48.15MUSD

67.47M AUD

Revenue (TTM)

$15.67MUSD

21.95M AUD

EBITDA (TTM)

$513.98KUSD

720.23K AUD

Net Income (TTM)

$683.59KUSD

957.91K AUD

EBITDA Margin

3.3%

Profit Margin

4.4%

PE Ratio

68.9

Forward PE

20.0

PS Ratio

3.1

PB Ratio

11.3

EV/EBITDA

82.5

Company Profile

Country (HQ)

Australia

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Blair William Brabin Norfolk open_in_new

Employees

Founded

2018

Website

biomeaustralia.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-1.7%	-10%	-6.3%	-35%	-35%	-29%	-32%	261%	127%

News

Markets

Exchange	Ticker	Price	Quotes
Australian Securities Exchange (ASX) MIC: XASX PRIMARY	BIO Biome Australia Ltd ISIN: AU0000184137 Shares Out.: Shares Outstanding: 227.998M¹ Shares Float: 141.963M² TV: TradingView: ASX: BIO SA: Stock Analysis: ASX: BIO YF: Yahoo Finance: BIO.AX GF: Google Finance: ASX: BIO BA: Barron's: BIO MS: Morningstar: XASX: BIO	0.2950 AUD	TV: TradingView: ASX: BIO SA: Stock Analysis: ASX: BIO YF: Yahoo Finance: BIO.AX GF: Google Finance: ASX: BIO BA: Barron's: BIO MS: Morningstar: XASX: BIO

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Biome Australia Ltd.

Biome Australia Limited engages in the development, commercialization, and marketing of various live biotherapeutics and complementary medicines in Australia and internationally. The company provides probiotics as live biotherapeutic products under the Activated Probiotics brand, and nutraceutical and complementary medicines under the Activated Therapeutics brand. It markets its products through community pharmacies, independent health practitioners, and health professionals. The company was incorporated in 2018 and is based in Collingwood, Australia.

Similar Companies

Industry: Drug Manufacturers - General (Australia)

Name	Market Cap (USD) diff.	PE	Country
Sigma Healthcare Ltd. ASX: SIG	$22.82B 31.98B AUD 47K%	52.3	Australia
PYC Therapeutics Ltd. ASX: PYC	$926.22M 1.3B AUD 2K%	-	Australia
Racura Oncology Ltd. ASX: RAC	$346.24M 485.18M AUD 609%	-	Australia
Clinuvel Pharmaceuticals Ltd. ASX: CUV	$335.4M 469.99M AUD 587%	14.5	Australia
Starpharma Holdings Ltd. ASX: SPL	$216.39M 303.23M AUD 343%	-	Australia
Mayne Pharma Group Ltd. ASX: MYX	$166.4M 233.18M AUD 241%	-	Australia

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 2M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 1M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 739K%	97.4	United States
Roche Holding AG SIX: RO	$324.68B 256.25B CHF 665K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.43B 215.59B GBP 593K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$277.35B 218.9B CHF 568K%	20.5	Switzerland

chevron_leftBack